DEA Boosts Amphetamine Quotas: More Meds for 2025 Without Overproduction
Published Date: 9/19/2025
Notice
Summary
The DEA is changing how much lisdexamfetamine and d-amphetamine can be made in 2025. This affects drug makers who need to follow new production limits to meet demand safely and legally. The update is happening quickly to stick to important deadlines, but it doesn’t involve any new costs for the public.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
2025 Production Limits for Two Stimulants
The DEA adjusted the 2025 aggregate production quota for the Schedule II substances lisdexamfetamine and d-amphetamine (for conversion). Drug manufacturers must follow the new 2025 production limits and the DEA expedited publication to meet the timeframes in 21 U.S.C. 826(h)(1).
No New Public Costs Announced
The DEA stated this adjustment does not involve any new costs for the public. The change is an administrative adjustment to 2025 production quotas and was published quickly to meet statutory timeframes.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-11572 — Ashley Vermillion, N.P.; Decision and Order
Ashley Vermillion, a nurse practitioner from Maine, lost her DEA registration because she no longer has the legal right to handle controlled substances in her state. She didn’t ask for a hearing, so the DEA moved forward and officially revoked her registration. This means she can’t prescribe or manage controlled drugs anymore, effective immediately.
2026-11416 — Importer of Controlled Substances Application: CalCog Inc.
CalCog Inc. wants to become an official importer of some powerful controlled substances like LSD and 5-MeO-DMT. People and companies involved with these drugs have until July 8, 2026, to share their thoughts or ask for a hearing. This move could shake up the import scene, but no costs or changes happen until the DEA decides.
2026-10380 — Schedules of Controlled Substances: Placement of Diphenidine in Schedule I
The DEA wants to put diphenidine, a drug, into Schedule I, which means it will be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or owns diphenidine, adding strict rules and penalties. You’ve got until June 25, 2026, to share your thoughts before the new rules might kick in.
2026-10253 — Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
Starting May 22, 2026, the DEA is putting 2-fluorodeschloroketamine (2-FDCK) into Schedule I, meaning it’s now treated like the most dangerous drugs. This affects anyone who makes, sells, or uses it, adding strict rules and serious penalties. The temporary ban lasts two years, giving the government time to decide if it should stay permanent.
Previous / Next Documents
Previous: 2025-18109 — Silicon Metal From Russia; Scheduling of an Expedited Five-Year Review
The government is speeding up a review to decide if special taxes on silicon metal from Russia should stay or go. This affects companies that buy or sell this metal, and could change prices or trade rules soon. The review aims to protect U.S. businesses from unfair competition while keeping things fair and clear.
Next: 2025-18112 — Agency Information Collection Activities; Comment Request; AmeriCorps State and National Project Progress Reports
AmeriCorps wants to keep collecting progress reports from groups they fund to make sure projects are on track and making a difference. This affects all AmeriCorps State and National programs, but there’s no new cost or extra paperwork—just a smooth renewal. They’re asking for public feedback before finalizing, so now’s the time to speak up!